Figure 1: Clinical trials for the top five indications by phase in 2017.

During an analysis of all clinical trials with a start date in 2017, GlobalData analysts found that pain was the most frequent indication across the period, followed by Type 2 diabetes, breast cancer, solid tumour, and non-small cell lung cancer.

Phase II was the phase with the majority of trials across the major indications, as shown in Figure 1, with the exception of solid tumour, which had the largest number of its trials in Phase I. The top two indications, Pain and Type 2 Diabetes, both showed a much higher number of Phase IV trials in comparison to the other three indications, at 26% and 24%, respectively.

Some types of pain and type 2 diabetes are chronic, so long-term studies with very large populations are important for patients with a continuous treatment programme.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.